Epstein–Barr virus in autoimmune diseases

and EA 3186 Agents Pathogènes et Inflammation, University of Franche Comté, Besançon, France.
Best practice & research. Clinical rheumatology (Impact Factor: 2.6). 11/2008; 22(5):883-96. DOI: 10.1016/j.berh.2008.09.007
Source: PubMed


Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjögren's syndrome (pSS) are complex disorders with a genetic background and the involvement of environmental factors, including viruses. The Epstein-Barr virus (EBV) is a plausible candidate for playing a role in the pathophysiology of these diseases. Both SLE and RA are characterized by high titers of anti-EBV antibodies and impaired T-cell responses to EBV antigens. Compared with normal subjects, elevated EBV load in peripheral blood has been observed in SLE and RA. EBV DNA or RNA has been evidenced in target organs of RA (synovium) or pSS (salivary glands). Finally, molecular mimicry has been demonstrated between EBV proteins and self antigens in these three conditions. In addition, SLE, RA, and pSS are associated with an increased risk of lymphoma with a potential role for EBV. The influence of new and emergent treatments of these autoimmune diseases (biological therapies) on EBV load and the course of latent EBV infection requires further studies.

Download full-text


Available from: Jean Roudier,
  • Source
    • "The primary EBV infection occurs asymptomatically in childhood and typically persists throughout the life of the host. EBV is the cause of infectious mononucleosis [7] and is associated with specific forms of cancer, including Hodgkin's lymphoma [8], Burkitt's lymphoma [9], and nasopharyngeal carcinoma [10], and with autoimmune diseases [11]. In most asymptomatic carriers, the virus is periodically replicated, and the infectious virus is known as the EBV lytic cycle, which has been found to be associated with an increasing number of diseases, such as rheumatoid arthritis [12] [13] and infectious mononucleosis [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Organophosphate pesticides (OPs) are among the most widely used synthetic chemicals for the control of a wide variety of pests, and reactive oxygen species (ROS) caused by OPs may be involved in the toxicity of various pesticides. Previous studies have demonstrated that a reactivation of latent Epstein-Barr virus (EBV) could be induced by oxidative stress. In this study, we investigated whether OPs could reactivate EBV through ROS accumulation. The Raji cells were treated with chlorpyrifos (CPF), one of the most commonly used OPs. Oxidative stress indicators and the expression of the EBV immediate-early gene BZLF-1 were determined after CPF treatment. Our results show that CPF induces oxidative stress as evidenced by decreased malondialdehyde (MDA) level, accompanied by an increase in ROS production, DNA damage, glutathione (GSH) level, and superoxide dismutase (SOD) and catalase (CAT) activity. Moreover, CPF treatment significantly enhances the expression of BZLF-1, and the increased BZLF-1 expression was ameliorated by N-acetylcysteine (NAC) incubation. These results suggest that OPs could contribute to the reactivation of the EBV lytic cycle through ROS induction, a process that may play an important role in the development of EBV-associated diseases.
    Oxidative Medicine and Cellular Longevity 08/2015; 2015(5):309125. DOI:10.1155/2015/309125 · 3.36 Impact Factor
  • Source
    • "[3] "

    Sjógren,s Syndrome, Edited by Eduardo M. Hernandez, 05/2014: chapter Chapter III: pages 71-96; Nova Science Publisher., ISBN: 978-1-63117-859-7
  • Source
    • "On the one hand, TLR2 and 4 are capable of recognizing endogenous proteins among which some are of synovial origin (Hsp60, fibrinogen, hyaluronic acid) [10-16]. On the other hand, TLR2 and 4 recognize infectious targets either latent or persistent in the organism [17-22]. TLRs have the capacity to initiate and maintain an inflammatory reaction in response to endogenous danger signals and thus represent good candidates for the long-term inflammation of RA [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to assess the capacity of dendrimer aza-bis-phosphonate (ABP) to modulate phenotype of monocytes (Mo) and monocytes derived dendritic cells (MoDC) activated in response to TLR4 and interferon gamma (IFNgamma) stimulation. Mo (n = 12) and MoDC (n = 11) from peripheral blood of healthy donors were prepared. Cells were preincubated or not for 1 hour with dendrimer ABP, then incubated with lipopolysaccharide (LPS; as a TLR4 ligand) and interferon-gamma (IFN-gamma) for 38 hours. Secretion of tumor necrosis factor alpha (TNFalpha), interleukin (IL) -1, IL-6, IL-12, IL-10 and IL-23 in the culture medium was measured by enzyme-linked immunosorbent assay (ELISA) and Cytokine Bead Array. Differentiation and subsequent maturation of MoDC from 9 donors in the presence of LPS were analyzed by flow cytometry using CD80, CD86, CD83 and CD1a surface expression as markers. Mo and MoDC were orientated to a pro-inflammatory state. In activated Mo, TNFalpha, IL-1beta and IL-23 levels were significantly lower after prior incubation with dendrimer ABP. In activated MoDC, dendrimer ABP promoted IL-10 secretion while decreasing dramatically the level of IL-12. TNFalpha and IL-6 secretion were significantly lower in the presence of dendrimer ABP. LPS driven maturation of MoDC was impaired by dendrimer ABP treatment, as attested by the significantly lower expression of CD80 and CD86. Our data indicate that dendrimer ABP possesses immunomodulatory properties on human Mo and MoDC, in a toll-like receptor 4 (TLR4) + IFN-gamma stimulation model, by inducing M2 alternative activation of Mo and promoting tolerogenic MoDC.
    Arthritis research & therapy 04/2014; 16(2):R98. DOI:10.1186/ar4546 · 3.75 Impact Factor
Show more